0001140361-16-088115.txt : 20161129 0001140361-16-088115.hdr.sgml : 20161129 20161129200749 ACCESSION NUMBER: 0001140361-16-088115 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161121 FILED AS OF DATE: 20161129 DATE AS OF CHANGE: 20161129 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200915291 FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: BUILDING 227, TETRICUS SCIENCE PARK STREET 2: PORTON DOWN CITY: SALISBURY, WILTSHIRE STATE: X0 ZIP: SP4 0JQ BUSINESS PHONE: 44 0 1980 753002 MAIL ADDRESS: STREET 1: BUILDING 227, TETRICUS SCIENCE PARK STREET 2: PORTON DOWN CITY: SALISBURY, WILTSHIRE STATE: X0 ZIP: SP4 0JQ FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Therapeutics, Inc. DATE OF NAME CHANGE: 20140916 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery, Inc DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery Inc DATE OF NAME CHANGE: 20060105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Resnick Joshua CENTRAL INDEX KEY: 0001690959 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36830 FILM NUMBER: 162023841 MAIL ADDRESS: STREET 1: ONE BOSTON PLACE STREET 2: 201 WASHINGTON STREET, SUITE 3900 CITY: BOSTON STATE: MA ZIP: 02108 4 1 doc1.xml FORM 4 X0306 4 2016-11-21 0 0001348911 KalVista Pharmaceuticals, Inc. KALV 0001690959 Resnick Joshua ONE BOSTON PLACE, SUITE 3900 201 WASHINGTON STREET, SUITE 3900 BOSTON MA 02108 1 0 0 0 Common Stock 2016-11-21 4 A 0 2508279 A 2508279 I By SV Life Sciences Fund IV, L.P. Common Stock 2016-11-21 4 A 0 71211 A 71211 I By SV Life Sciences Fund IV Strategic Partners, L.P. Received in exchange for 6,730,810 shares of KalVista Pharmaceuticals, Ltd. Series A Preferred Shares and 1,885,228 shares of Series B Preferred Shares in connection with the closing of the share purchase transaction (the "Transaction") whereby KalVista Pharmaceuticals, Ltd. became a wholly-owned subsidiary of Carbylan Therapeutics, Inc., which changed its name to KalVista Pharmaceuticals, Inc. (the "Company"). On the effective date of the Transaction, the closing price of the Company's common stock was $9.38 per share. All numbers give effect to the 14:1 reverse stock split effected by the Company on November 21, 2016 (the "Reverse Stock Split"). Prior to the Reverse Stock Split, the closing price of the Company's common stock was $0.67 per share. SV Life Sciences Fund IV Strategic Partners, L.P., a Delaware limited partnership, and (ii) SV Life Sciences Fund IV, L.P., a Delaware limited partnership. The general partner of both SV Life Sciences Fund IV, L.P. and SV Life Sciences Fund IV Strategic Partners, L.P. (collectively, the "Funds") is SV Life Sciences Fund IV (GP), L.P. The general partner of SV Life Sciences Fund IV (GP), L.P. is SVLSF IV, LLC. Both SV Life Sciences Fund IV (GP), L.P. and SVLS IV, LLC may be deemed to beneficially own the shares held by the Funds. SV Life Sciences Fund IV (GP), L.P. and SVLS IV, LLC may be deemed to beneficially own the shares held by the Funds. SV Life Sciences Fund IV (GP), L.P. and SVLS IV, LLC disclaim beneficial ownership of the shares held by the Funds except to the extent of any pecuniary interest therein. Dr. Resnick, a director of Issuer, is a partner of SV Life Sciences. Received in exchange for 191,091 shares of KalVista Pharmaceuticals, Ltd. Series A Preferred Shares and 53,523 shares of Series B Preferred Shares in connection with the closing of the Transaction. On the effective date of the Transaction, the closing price of the Company's common stock was $9.38 per share. All numbers give effect to the Reverse Stock Split. Prior to the Reverse Stock Split, the closing price of the Company's common stock was $0.67 per share. /s/Joshua Resnick 2016-11-29